Silvan Tuerkcan
Stock Analyst at JMP Securities
(1.40)
# 3,236
Out of 4,826 analysts
163
Total ratings
33.76%
Success rate
-11.02%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FHTX Foghorn Therapeutics | Reiterates: Market Outperform | $9 | $3.94 | +128.43% | 2 | Apr 30, 2025 | |
| ENGN enGene Holdings | Reiterates: Market Outperform | $18 | $3.68 | +389.13% | 4 | Apr 29, 2025 | |
| TSHA Taysha Gene Therapies | Reiterates: Market Outperform | $5 | $2.46 | +103.67% | 12 | Apr 28, 2025 | |
| NUVB Nuvation Bio | Initiates: Market Outperform | $6 | $2.39 | +151.05% | 1 | Apr 23, 2025 | |
| TERN Terns Pharmaceuticals | Reiterates: Market Outperform | $20 | $3.31 | +505.14% | 12 | Apr 21, 2025 | |
| EXEL Exelixis | Reiterates: Market Outperform | $41 | $39.84 | +2.91% | 21 | Apr 17, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $18 → $20 | $14.70 | +36.05% | 11 | Apr 10, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Market Outperform | $17 | $1.41 | +1,105.67% | 5 | Mar 26, 2025 | |
| ELEV Elevation Oncology | Downgrades: Market Perform | $7 | $0.33 | +2,016.72% | 7 | Mar 21, 2025 | |
| GBIO Generation Bio Co. | Reiterates: Market Perform | n/a | $0.41 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $4.24 | +253.77% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $10 | $1.57 | +538.98% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $86 | $37.62 | +128.60% | 14 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $70 | $5.24 | +1,237.15% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $0.86 | +365.22% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $3.31 | +534.44% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $12 | $0.60 | +1,885.44% | 11 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.66 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $1.57 | +282.17% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $273.31 | +2.45% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $11.86 | +51.77% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.45 | - | 10 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $2 → $3 | $6.99 | -57.08% | 3 | May 10, 2022 |
Foghorn Therapeutics
Apr 30, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $3.94
Upside: +128.43%
enGene Holdings
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $3.68
Upside: +389.13%
Taysha Gene Therapies
Apr 28, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $2.46
Upside: +103.67%
Nuvation Bio
Apr 23, 2025
Initiates: Market Outperform
Price Target: $6
Current: $2.39
Upside: +151.05%
Terns Pharmaceuticals
Apr 21, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $3.31
Upside: +505.14%
Exelixis
Apr 17, 2025
Reiterates: Market Outperform
Price Target: $41
Current: $39.84
Upside: +2.91%
Benitec Biopharma
Apr 10, 2025
Maintains: Market Outperform
Price Target: $18 → $20
Current: $14.70
Upside: +36.05%
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.41
Upside: +1,105.67%
Elevation Oncology
Mar 21, 2025
Downgrades: Market Perform
Price Target: $7
Current: $0.33
Upside: +2,016.72%
Generation Bio Co.
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.41
Upside: -
Mar 7, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $4.24
Upside: +253.77%
Mar 4, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $1.57
Upside: +538.98%
Feb 13, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $37.62
Upside: +128.60%
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $70
Current: $5.24
Upside: +1,237.15%
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $0.86
Upside: +365.22%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $3.31
Upside: +534.44%
Dec 10, 2024
Reiterates: Market Outperform
Price Target: $12
Current: $0.60
Upside: +1,885.44%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.66
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $1.57
Upside: +282.17%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $273.31
Upside: +2.45%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $11.86
Upside: +51.77%
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.45
Upside: -
May 10, 2022
Maintains: Market Outperform
Price Target: $2 → $3
Current: $6.99
Upside: -57.08%